Anti-VEGF agents such as ranibizumab are approved by the US Food and Drug Administration (FDA) and European Medicines Agency for treatment of DME, DR, Retinal Vein Occlusion (RVO), and AMD. This evidence concerns the gene VEGFA and retinal vein occlusion.